Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Indapamide

FDA-approved product (tablet, oral), marketed as Indapamide, Lozol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Indapamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Hypertension
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Indapamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Indapamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Empiric Versus Selective Prevention Strategies for Kidney Stone Disease

    NCT05365477 · start 2022-08-04

    Registered record
    Registry ID
    NCT05365477
    Conditions
    Kidney Stones; Nephrolithiasis
    Interventions
    Empiric Therapy: Diet; Empiric Therapy: Drug; Selective Therapy: Diet; Selective Therapy: Drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-04
    Completion
    2026-03-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones; Nephrolithiasis
    InterventionEmpiric Therapy: Diet; Empiric Therapy: Drug; Selective Therapy: Diet; Selective Therapy: Drug
    PhasePhase 4
    Registry statusCompleted

  • Low-dose Quadruple Combination Therapy in Patients With Hypertension

    NCT05377203 · start 2022-07-13

    Registered record
    Registry ID
    NCT05377203
    Conditions
    Hypertension; Arterial Hypertension
    Interventions
    Quadruple combination of half doses therapy→Dual combination of standard dose therapy; Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-07-13
    Completion
    2023-07-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Arterial Hypertension
    InterventionQuadruple combination of half doses therapy→Dual combination of standard dose therapy; Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Leningrado Association in the Treatment of Hypertension

    NCT03814109 · start 2022-04

    Registered record
    Registry ID
    NCT03814109
    Conditions
    Arterial Hypertension
    Interventions
    LENINGRADO association; Indapamide SR 1.5 MG; Levamlodipine 2.5/ 5 mg; Leningrado association Placebo; Indapamide SR Placebo; Levamlodipine placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-04
    Completion
    2024-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionLENINGRADO association; Indapamide SR 1.5 MG; Levamlodipine 2.5/ 5 mg; Leningrado association Placebo +2 more
    PhasePhase 3
    Registry statusWithdrawn

  • Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

    NCT06212648 · start 2022-03-25

    Registered record
    Registry ID
    NCT06212648
    Conditions
    Hypertension; Essential Hypertension
    Interventions
    SPC1001 High; SPC1001 Mid1; SPC1001 Mid2; SPC1001 Low; SPC3001; SPC4001; SPC4002; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-03-25
    Completion
    2023-01-27
    Enrolment
    253

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Essential Hypertension
    InterventionSPC1001 High; SPC1001 Mid1; SPC1001 Mid2; SPC1001 Low +4 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to Therapy

    NCT05899920 · start 2022-03-11

    Registered record
    Registry ID
    NCT05899920
    Conditions
    Resistant Arterial Hypertension
    Interventions
    Blood samples will be taken for pharmacokinetics and pharmacogenetics
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-03-11
    Completion
    2024-12-31
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResistant Arterial Hypertension
    InterventionBlood samples will be taken for pharmacokinetics and pharmacogenetics
    PhaseNot applicable
    Registry statusUnknown

  • Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD

    NCT05169021 · start 2021-12-31

    Registered record
    Registry ID
    NCT05169021
    Conditions
    Cerebral Small Vessel Diseases; Stroke
    Interventions
    Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy; Amlodipine+intensive antihypertensive therapy; Amlodipine+standard antihypertensive therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2021-12-31
    Completion
    2028-12-31
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Small Vessel Diseases; Stroke
    InterventionAmlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy; Amlodipine+intensive antihypertensive therapy; Amlodipine+standard antihypertensive therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

    NCT05103332 · start 2021-11-05

    Registered record
    Registry ID
    NCT05103332
    Conditions
    Hypertension
    Interventions
    Indapamide; Amlodipine; Olmesartan; Placebo; Zilebesiran
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-11-05
    Completion
    2024-09-13
    Enrolment
    663

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIndapamide; Amlodipine; Olmesartan; Placebo +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy Volunteers

    NCT05097794 · start 2021-08-16

    Registered record
    Registry ID
    NCT05097794
    Conditions
    Hypertension
    Interventions
    BR1015-1; BR1015-2; BR1015-1 + BR1015-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-08-16
    Completion
    2021-10-22
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionBR1015-1; BR1015-2; BR1015-1 + BR1015-2
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

    NCT04518293 · start 2021-07-09

    Registered record
    Registry ID
    NCT04518293
    Conditions
    Hypertension
    Interventions
    Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg; telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg; Telmisartan 20 mg/amlodipine 2.5 mg; telmisartan 40 mg/amlodipine 5 mg; Telmisartan 20 mg/indapamide 1.25 mg; telmisartan 40 mg/indapamide 2.5 mg; Amlodipine 2.5 mg/indapamide 1.25 mg; amlodipine 5 mg/indapamide 2.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-07-09
    Completion
    2023-09-01
    Enrolment
    1,385

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg; telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg; Telmisartan 20 mg/amlodipine 2.5 mg; telmisartan 40 mg/amlodipine 5 mg +4 more
    PhasePhase 3
    Registry statusCompleted

  • Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

    NCT04686643 · start 2021-02-01

    Registered record
    Registry ID
    NCT04686643
    Conditions
    Hypertension
    Interventions
    AGSAVI; AGLS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-02-01
    Completion
    2022-05-01
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAGSAVI; AGLS
    PhasePhase 3
    Registry statusUnknown

  • Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

    NCT03785067 · start 2020-02-27

    Registered record
    Registry ID
    NCT03785067
    Conditions
    Cognitive Decline; Intracerebral Hemorrhage; Dementia, Vascular; Cerebral Small Vessel Diseases; Hypertension; Stroke Hemorrhagic
    Interventions
    telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-02-27
    Completion
    2021-02-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive Decline; Intracerebral Hemorrhage; Dementia, Vascular; Cerebral Small Vessel Diseases +2 more
    Interventiontelmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg; Placebo oral capsule
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

    NCT03640312 · start 2019-08-30

    Registered record
    Registry ID
    NCT03640312
    Conditions
    Hypertension
    Interventions
    QUARTET LDQT; Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-08-30
    Completion
    2024-07-31
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionQUARTET LDQT; Candesartan
    PhasePhase 2
    Registry statusCompleted

  • Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)

    NCT04040634 · start 2019-08-08

    Registered record
    Registry ID
    NCT04040634
    Conditions
    Diabetes Mellitus; High Blood Pressure; Cardiovascular Diseases; Cognitive Impairment
    Interventions
    Intensive Control of Systolic Blood Pressure (SBP); Standard control of Systolic Blood Pressure (SBP)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-08-08
    Completion
    2026-07-08
    Enrolment
    9,476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; High Blood Pressure; Cardiovascular Diseases; Cognitive Impairment
    InterventionIntensive Control of Systolic Blood Pressure (SBP); Standard control of Systolic Blood Pressure (SBP)
    PhaseNot applicable
    Registry statusCompleted

  • Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients

    NCT04036409 · start 2019-08-05

    Registered record
    Registry ID
    NCT04036409
    Conditions
    Ischemic Stroke; Blood Pressure; Cognitive Impairment; Vascular Diseases
    Interventions
    Intensive Control of Systolic Blood Pressure (SBP); Standard control of Systolic Blood Pressure (SBP)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-08-05
    Completion
    2026-07-08
    Enrolment
    4,368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Blood Pressure; Cognitive Impairment; Vascular Diseases
    InterventionIntensive Control of Systolic Blood Pressure (SBP); Standard control of Systolic Blood Pressure (SBP)
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension

    NCT03814148 · start 2019-06

    Registered record
    Registry ID
    NCT03814148
    Conditions
    Arterial Hypertension
    Interventions
    LENINGRADO 5 association; Natrilix® SR; Natrilix SR Placebo; Leningrado 5 association Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2020-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionLENINGRADO 5 association; Natrilix® SR; Natrilix SR Placebo; Leningrado 5 association Placebo
    PhasePhase 3
    Registry statusWithdrawn